Cancer immunotherapy has shown long-lasting responses in metastatic cancers, but resistance mechanisms limit its effectiveness. Resistance can be primary (initial lack of response) or acquired (relapse after initial response). Understanding these mechanisms is crucial for improving clinical outcomes. Primary resistance often results from lack of tumor antigen recognition or failure to present antigens on MHC. Adaptive resistance involves tumor cells evolving to evade immune responses, such as through PD-L1 expression or interferon signaling defects. Acquired resistance may arise from loss of tumor antigen expression, mutations, or changes in the tumor microenvironment. Tumor-intrinsic factors include genetic alterations like PTEN loss, WNT signaling, or PD-L1 overexpression, which can inhibit immune responses. Tumor-extrinsic factors involve immune cells like Tregs, MDSCs, and M2 macrophages that suppress anti-tumor immunity. These cells can be targeted to enhance immunotherapy effectiveness. Checkpoint inhibitors like anti-CTLA-4 and anti-PD-1 have shown promise, but resistance remains a challenge. Combination therapies, such as anti-CTLA-4 plus anti-PD-1, have improved responses in melanoma. Other strategies include using CAR T cells, adoptive T cell transfer, and epigenetic modifiers to enhance immune responses. Monitoring resistance mechanisms is critical for personalized treatment. Biomarkers like mutational load and immune infiltrate levels help predict response. Longitudinal analysis of tumor samples can identify dynamic changes in immune responses. Strategies to convert "cold" tumors into "hot" ones include immunomodulatory agents, targeted therapies, and combination approaches with immunotherapy. Combination therapies, such as checkpoint inhibitors with targeted drugs or immunomodulators, are being tested to overcome resistance. These approaches aim to enhance T cell function, reduce immunosuppressive factors, and improve tumor antigen presentation. Ongoing research focuses on optimizing these strategies to improve clinical outcomes for cancer patients.Cancer immunotherapy has shown long-lasting responses in metastatic cancers, but resistance mechanisms limit its effectiveness. Resistance can be primary (initial lack of response) or acquired (relapse after initial response). Understanding these mechanisms is crucial for improving clinical outcomes. Primary resistance often results from lack of tumor antigen recognition or failure to present antigens on MHC. Adaptive resistance involves tumor cells evolving to evade immune responses, such as through PD-L1 expression or interferon signaling defects. Acquired resistance may arise from loss of tumor antigen expression, mutations, or changes in the tumor microenvironment. Tumor-intrinsic factors include genetic alterations like PTEN loss, WNT signaling, or PD-L1 overexpression, which can inhibit immune responses. Tumor-extrinsic factors involve immune cells like Tregs, MDSCs, and M2 macrophages that suppress anti-tumor immunity. These cells can be targeted to enhance immunotherapy effectiveness. Checkpoint inhibitors like anti-CTLA-4 and anti-PD-1 have shown promise, but resistance remains a challenge. Combination therapies, such as anti-CTLA-4 plus anti-PD-1, have improved responses in melanoma. Other strategies include using CAR T cells, adoptive T cell transfer, and epigenetic modifiers to enhance immune responses. Monitoring resistance mechanisms is critical for personalized treatment. Biomarkers like mutational load and immune infiltrate levels help predict response. Longitudinal analysis of tumor samples can identify dynamic changes in immune responses. Strategies to convert "cold" tumors into "hot" ones include immunomodulatory agents, targeted therapies, and combination approaches with immunotherapy. Combination therapies, such as checkpoint inhibitors with targeted drugs or immunomodulators, are being tested to overcome resistance. These approaches aim to enhance T cell function, reduce immunosuppressive factors, and improve tumor antigen presentation. Ongoing research focuses on optimizing these strategies to improve clinical outcomes for cancer patients.